
Selim Cellek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4720521/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: An insight into endotoxin shock. Biochemical and Biophysical Research Communications, 1990, 173, 541-547.	1.0	598
2	cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 1480-1485.	3.3	434
3	RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: A mechanism for diabetes-associated erectile dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9121-9126.	3.3	297
4	Two Phases of Nitrergic Neuropathy in Streptozotocin-Induced Diabetic Rats. Diabetes, 2003, 52, 2353-2362.	0.3	169
5	Selective nitrergic neurodegeneration in diabetes mellitus-a nitric oxide-dependent phenomenon. British Journal of Pharmacology, 1999, 128, 1804-1812.	2.7	159
6	Pathophysiology of Erectile Dysfunction. Journal of Sexual Medicine, 2005, 2, 26-39.	0.3	155
7	Physiology of Erectile Function. Journal of Sexual Medicine, 2004, 1, 254-265.	0.3	112
8	Y-27632, A Rho-Kinase Inhibitor, Inhibits Proliferation and Adrenergic Contraction of Prostatic Smooth Muscle Cells. Journal of Urology, 2003, 170, 2517-2522.	0.2	103
9	Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: A new insight into selective nitrergic neuropathy in diabetes. Diabetologia, 2004, 47, 331-339.	2.9	100
10	Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. British Journal of Pharmacology, 2001, 133, 455-458.	2.7	94
11	Human and rabbit cavernosal smooth muscle cells express Rho-kinase. International Journal of Impotence Research, 2002, 14, 1-7.	1.0	85
12	Nitrergic control of peripheral sympathetic responses in the human corpus cavernosum: A comparison with other species. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 8226-8231.	3.3	79
13	The Role of Intrinsic Pathway in Apoptosis Activation and Progression in Peyronie's Disease. BioMed Research International, 2014, 2014, 1-10.	0.9	77
14	GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterology and Motility, 2009, 21, 657.	1.6	75
15	Nitrergic neurotransmission mediates the non-adrenergic non-cholinergic responses in the clitoral corpus cavernosum of the rabbit. British Journal of Pharmacology, 1998, 125, 1627-1629.	2.7	68
16	5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Neurogastroenterology and Motility, 2006, 18, 853-861.	1.6	63
17	Inhibition of nitrergic relaxations by a selective inhibitor of the soluble guanylate cyclase. British Journal of Pharmacology, 1996, 118, 137-140.	2.7	59
18	BAY41-2272, a Novel Nitric Oxide Independent Soluble Guanylate Cyclase Activator, Relaxes Human and Rabbit Corpus Cavernosum In Vitro. Journal of Urology, 2003, 169, 761-766.	0.2	59

SELIM CELLEK

#	Article	IF	CITATIONS
19	Investigation of cavernosal smooth muscle dysfunction in low flow priapism using an in vitro model. International Journal of Impotence Research, 2005, 17, 10-18.	1.0	58
20	Demonstration of Functional Neuronal β3-Adrenoceptors Within the Enteric Nervous System. Gastroenterology, 2007, 133, 175-183.	0.6	56
21	Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications. Current Pharmaceutical Design, 2004, 10, 3683-3695.	0.9	55
22	The Breakdown of Preformed Advanced Glycation End Products Reverses Erectile Dysfunction in Streptozotocinâ€Induced Diabetic Rats: Preventive Versus Curative Treatment. Journal of Sexual Medicine, 2006, 3, 242-252.	0.3	54
23	Fatty Acylation of Phospholipase D1 on Cysteine Residues 240 and 241 Determines Localization on Intracellular Membranes. Journal of Biological Chemistry, 1999, 274, 30023-30027.	1.6	51
24	Sexual Enhancement Products for Sale Online: Raising Awareness of the Psychoactive Effects of Yohimbine, Maca, Horny Goat Weed, and <i>Ginkgo biloba</i> . BioMed Research International, 2014, 2014, 1-13.	0.9	50
25	Visualisation of nitric oxide released by nerve stimulation. , 1997, 47, 224-232.		44
26	Characterization of the non-nitrergic NANC relaxation responses in the rabbit vaginal wall. British Journal of Pharmacology, 2002, 135, 546-554.	2.7	42
27	Pathophysiology of diabetic erectile dysfunction: potential contribution of vasa nervorum and advanced glycation endproducts. International Journal of Impotence Research, 2013, 25, 1-6.	1.0	41
28	Visualisation of Nitric Oxide Generated by Activated Murine Macrophages. Biochemical and Biophysical Research Communications, 1996, 221, 37-41.	1.0	40
29	Characterization of nitrergic neurotransmission during shortâ€and longâ€ŧerm electrical stimulation of the rabbit anococcygeus muscle. British Journal of Pharmacology, 1995, 115, 1149-1154.	2.7	34
30	Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH–LUTS. Nature Reviews Urology, 2014, 11, 231-241.	1.9	34
31	Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models. European Urology, 2019, 75, 329-340.	0.9	34
32	Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease. Sexual Medicine Reviews, 2019, 7, 679-689.	1.5	33
33	BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. Journal of Urology, 2003, 169, 761-6.	0.2	29
34	A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction. Expert Opinion on Investigational Drugs, 2002, 11, 1563-1573.	1.9	28
35	Nitrergic-noradrenergic interaction in penile erection: A new insight into erectile dysfunction. Drugs of Today, 2000, 36, 135.	0.7	28
36	Hierarchy of Membrane-targeting Signals of Phospholipase D1 Involving Lipid Modification of a Pleckstrin Homology Domain. Journal of Biological Chemistry, 2002, 277, 29152-29161.	1.6	27

SELIM CELLEK

#	Article	IF	CITATIONS
37	Nitrergic Neurodegeneration in Cerebral Arteries of Streptozotocin-Induced Diabetic Rats: A New Insight into Diabetic Stroke. Diabetes, 2005, 54, 212-219.	0.3	24
38	Early Effect of Bariatric Surgery on Urogenital Function in Morbidly Obese Men. Journal of Sexual Medicine, 2017, 14, 205-214.	0.3	24
39	NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. International Journal of Impotence Research, 2004, 16, 195-200.	1.0	23
40	ORIGINAL RESEARCH—BASIC SCIENCE: A Nitric Oxideâ€Releasing PDE5 Inhibitor Relaxes Human Corpus Cavernosum in the Absence of Endogenous Nitric Oxide. Journal of Sexual Medicine, 2005, 2, 53-57.	0.3	22
41	Synergy between 5â€HT ₄ receptor activation and acetylcholinesterase inhibition in human colon and rat forestomach. Neurogastroenterology and Motility, 2008, 20, 539-545.	1.6	22
42	A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats. International Journal of Impotence Research, 2004, 16, 479-485.	1.0	21
43	The β3-Adrenoceptor Agonist GW427353 (Solabegron) Decreases Excitability of Human Enteric Neurons via Release of Somatostatin. Gastroenterology, 2010, 138, 266-274.	0.6	21
44	Feasibility-Usability Study of a Tablet App Adapted Specifically for Persons with Cognitive Impairment—SMART4MD (Support Monitoring and Reminder Technology for Mild Dementia). International Journal of Environmental Research and Public Health, 2020, 17, 6816.	1.2	21
45	Potentiation by cholinesterase inhibitors of cholinergic activity in rat isolated stomach and colon. Pharmacological Research, 2008, 58, 297-301.	3.1	20
46	Understanding the Role of Adenosine Receptors in the Myofibroblast Transformation in Peyronie's Disease. Journal of Sexual Medicine, 2018, 15, 947-957.	0.3	18
47	Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease. Journal of Sexual Medicine, 2020, 17, 1848-1864.	0.3	15
48	Morphological, Chemical and Functional Analysis of Catuaba Preparations. Planta Medica, 2004, 70, 993-1000.	0.7	14
49	Common Pitfalls in Some of the Experimental Studies in Erectile Function and Dysfunction: A Consensus Article. Journal of Sexual Medicine, 2012, 9, 2770-2784.	0.3	14
50	Visualization of nitric oxide formation in cell cultures and living tissue. Acta Physiologica Scandinavica, 1999, 167, 161-166.	2.3	13
51	Regulation of the cardiovascular system by non-adrenergic non-chollnergic nerves. Current Opinion in Nephrology and Hypertension, 1997, 6, 74-79.	1.0	11
52	Nitrergic modulation of cholinergic responses in the opossum lower oesophageal sphincter. British Journal of Pharmacology, 1997, 122, 1043-1046.	2.7	11
53	The Rho-kinase inhibitor Y-27632 and the soluble guanylyl cyclase activator BAY41-2272 relax rabbit vaginal wall and clitoral corpus cavernosum. British Journal of Pharmacology, 2003, 138, 287-290.	2.7	11
54	Functional evidence for nitrergic neurotransmission in a human clitoral corpus cavernosum: a case study. International Journal of Impotence Research, 2004, 16, 319-324.	1.0	11

SELIM CELLEK

#	Article	IF	CITATIONS
55	Modulation of Noradrenergic Responses by Nitric Oxide from Inducible Nitric Oxide Synthase. Nitric Oxide - Biology and Chemistry, 1997, 1, 204-210.	1.2	10
56	The investigation of putative agents, using an <i> in vitro</i> model, to prevent cavernosal smooth muscle dysfunction during lowâ€flow priapism. BJU International, 2008, 102, 988-992.	1.3	10
57	Current oral treatments for erectile dysfunction. Expert Opinion on Pharmacotherapy, 2002, 3, 1613-1629.	0.9	9
58	Let's make NO mistake!. International Journal of Impotence Research, 2005, 17, 388-389.	1.0	9
59	Challenges in sexual medicine. Nature Reviews Urology, 2012, 9, 537-542.	1.9	8
60	Single-cell Transcriptomics Uncover a Novel Role of Myeloid Cells and T-lymphocytes in the Fibrotic Microenvironment in Peyronie's Disease. European Urology Focus, 2022, 8, 814-828.	1.6	8
61	Purines and pyrimidines are not involved in NANC relaxant responses in the rabbit vaginal wall. British Journal of Pharmacology, 2002, 137, 513-521.	2.7	7
62	Cholesterol feeding attenuates endothelium-dependent relaxation response to acetylcholine in the main pulmonary artery of chickens. European Journal of Pharmacology, 1986, 129, 397-400.	1.7	6
63	Unwinding Fibrosis in Peyronie's Disease. Journal of Sexual Medicine, 2020, 17, 838-840.	0.3	5
64	Associations Between Mobile Health Technology use and Self-rated Quality of Life: A Cross-sectional Study on Older Adults with Cognitive Impairment. Gerontology and Geriatric Medicine, 2021, 7, 233372142110189.	0.8	5
65	Solving a bottleneck in animal models of peyronie′s disease. Asian Journal of Andrology, 2014, 16, 639.	0.8	3
66	5-hydroxyindalpine, an agonist at the putative 5-HT1Preceptor, has no activity on human recombinant monoamine receptors but accelerates distension-induced peristalsis in mouse isolated colon. Neurogastroenterology and Motility, 2009, 21, 760-e48.	1.6	2
67	Vasa Nervorum in Rat Major Pelvic Ganglion are Innervated by Nitrergic Nerve Fibers. Journal of Sexual Medicine, 2013, 10, 2967-2974.	0.3	2
68	BAY41-2272, a Novel Nitric Oxide Independent Soluble Guanylate Cyclase Activator, Relaxes Human and Rabbit Corpus Cavernosum In Vitro. Journal of Urology, 2003, , 761-766.	0.2	2
69	Histone deacetylase inhibition: a new target for <scp>P</scp> eyronie's disease?. BJU International, 2014, 114, 796-796.	1.3	0
70	PS-08-017 Early effect of bariatric surgery on urogenital function in morbidly obese male patients. Journal of Sexual Medicine, 2016, 13, S116.	0.3	0
71	016 Development of a High-Throughput, Cell-Based Assay for Anti-Myofibroblast Activity in Peyronie's Disease. Journal of Sexual Medicine, 2016, 13, S8.	0.3	0
72	PS-04-004 First results from a novel cell-based assay for anti-myofibroblast activity in Peyronie's disease. Journal of Sexual Medicine, 2016, 13, S89.	0.3	0